CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...

The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...

CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...

Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® ...

A woman suffering debilitating symptoms is crediting WVU Medicine for giving her her life back after finally receiving a ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CSL’s Andembry (garadacimab) to prevent ...

The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...

The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid ...

RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX), a biotechnology company with impressive revenue growth of nearly 30% over the last twelve months, has announced that ...

ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits ...

Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...